The Center
Multiple Sclerosis Center Dresden
Patient Information
Contact MSC
Physicians & Nurses
Study Team
Neuropsychology
Mobility Center
The Mobility Center
Walking Assessment
Jump Assessment
DIERS
EMIQ
Projects
Neuroimmunological Laboratory
The NIL
Neurofilament light chain
Autonomic & Neuroendocrinological Functional Laboratory
The ANF
ANF Assessment
MS Living Lab
Management & Science
Team Management & Science
Projects
eHealth & Analytics
MSDS 3D
MSDS Clinic & Practice
MS-HRS
MTRS
Multiple Sclerosis Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
English (UK)
Deutsch
English (UK)
Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC)
NIL
Jahr
Publikationsjahr
2022
Autoren
Autorenliste der Publikation
Ziemssen T, Groth M, Rauser B, Bopp T.
Verlag
Publisher-Information
Ther Adv Neurol Disord 2022;15.
Link
Zur Publikation (externer Server)
https://doi.org/10.1177/17562864221135305
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
Neuroimmunologie
Treatments
NIL
2022
Insights from Real-World Practice: The Dynamics of SARS-CoV-2 Infections and Vaccinations in a Large German Multiple Sclerosis Cohort
NIL
Jahr
2024
Preferences, Adherence, and Satisfaction: Three Years of Treatment Experiences of People with Multiple Sclerosis
MASC
Jahr
2024
Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab
MS Treatments
Jahr
2024
Effects of obstructive sleep apnea treatment on neurodegenerative biomarker neurofilament light chain and cognitive performance
NIL
Jahr
2024
Neue Therapieansätze bei Multipler Sklerose inkl. Stellenwert älterer Präparate
MS Treatments
Jahr
2024